Tyra Biosciences to Present at Upcoming Investor Conferences

Rhea-AI Summary

Tyra Biosciences, Inc. (TYRA) announced their participation in upcoming investor conferences to present a company overview and engage in one-on-one meetings with investors. The conferences include TD Cowen's 44th Annual Healthcare Conference, Jefferies Biotech On the Bay Summit, and Barclays 26th Annual Global Healthcare Conference. Todd Harris, CEO of TYRA, will lead the presentations and discussions.

CARLSBAD, Calif., Feb. 27, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences:

• TD Cowen's 44^th Annual Healthcare Conference, March 4-6th: Todd Harris, CEO of TYRA, will present a company overview on Wednesday, March 6, 2024, at 2:10 pm ET.  TYRA management will also participate in one-on-one meetings with investors during the conference.
• Jefferies Biotech On the Bay Summit, March 11-13th: TYRA management will participate in one-on-one meetings with investors during the conference. 
• Barclays 26^th Annual Global Healthcare Conference, March 12-14^th: Todd Harris, CEO of TYRA, will participate in a fireside chat on Thursday, March 14^th, 2024, at 8:00 am ET.  TYRA management will also participate in one-on-one meetings with investors during the conference.

A live and archived webcast of the Cowen presentation and Barclays fireside chat will be available via the For Investors page on the Investor section of the TYRA website. 

About Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA.

For more information about our science, pipeline and people, please visit  www.tyra.bio and engage with us on LinkedIn.

Contact:
Amy Conrad
aconrad@tyra.bio

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-upcoming-investor-conferences-302072664.html

SOURCE Tyra Biosciences

FAQ

When is Todd Harris, CEO of TYRA, scheduled to present a company overview at TD Cowen's 44th Annual Healthcare Conference?

Todd Harris will present on Wednesday, March 6, 2024, at 2:10 pm ET.

Which conference will TYRA management participate in one-on-one meetings with investors?

TYRA management will engage in one-on-one meetings with investors during Jefferies Biotech On the Bay Summit and Barclays 26th Annual Global Healthcare Conference.

Where can investors access the live and archived webcast of the Cowen presentation and Barclays fireside chat?

Investors can access the webcast on the For Investors page on the Investor section of the TYRA website.